EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Epidemiology and diagnostic challenges in neuromyelitis optica spectrum disorder in Taiwan: a hospital-based surveillance accompanied by a nationwide study

Jung Lung Hsu iD, Jen Jen Su, Mei-Yun Cheng, Ming-Feng Liao, Hung-Chou Kuo, Chun-Che Chu, Chiung-Mei Chen, Kuo-Hsuan Chang iD, Chun-Wei Chang, Yih-Ru Wu, Chin-Chang Huang, Chyi-Huey Bai und 1 weitere

Brain Communications · 03.07.2025 · 7 (4)

DOI: 10.1093/braincomms/fcaf293 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Brain Communications, online erschienen am 14.08.2025. Verfasst von Jung Lung Hsu und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, New Taipei Municipal TuCheng Hospital (Built and Operated by Chang Gung Medical Foundation), New Taipei City 236017, Taiwan. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Chugai Pharma Taiwan Co, Ltd, Chang Gung Memorial Hospital Research Fund.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Neuromyelitis optica spectrum disorder is a rare autoimmune inflammatory demyelinating disease that must be differentiated from multiple sclerosis. The impact of misclassification on these patients in Taiwan remains unclear. We conducted a hospital-based retrospective cohort study of neuromyelitis optica spectrum disorder patients using the Chang Gung Research Database from 2005 to 2021. This cohort included diagnostic serostatus data from anti-Aquaporin 4 antibody testing, providing insights into incidence, demographics, annual relapse rate, and initial misclassification as multiple sclerosis. To extend these findings, we applied the same methodology to a nationwide neuromyelitis optica spectrum disorder cohort (2006–2020) using Taiwan’s National Health Insurance Research Database, which does not include aquaporin 4 serostatus information; thus, the data made it impossible to distinguish seropositive from seronegative nationwide neuromyelitis optica spectrum disorder cases. Misclassification was calculated as the ratio of nationwide neuromyelitis optica spectrum disorder patients initially diagnosed with multiple sclerosis (MS) to the total nationwide neuromyelitis optica spectrum disorder cases in each cohort. In the Chang Gung Research Database cohort, we identified 193 seropositive nationwide neuromyelitis optica spectrum disorder patients, including four (2.1%) paediatric cases. Hospital incidence increased from 0.08 to 1.19 per 100 000 persons (2006–2021). Comorbidities were present in 32% of adults, with Sjögren’s syndrome as the most common (21.2%). Median annualized relapse rate in adults was 0.49 (range, 0.26–0.85) and was higher in the first 3 years post-diagnosis (0.67 versus 0.00; P < 0.01). The National Health Insurance Research Database cohort included 1892 neuromyelitis optica spectrum disorder patients, 92 (4.9%) paediatric. Incidence in adults rose from 0.25 to 0.84 per 100 000 persons, with a prevalence of 8.01 per 100 000 in 2020. Median annualized relapse rate was 0.36 (range, 0.07–60.83) for adults and 0.44 (range, 0.07–6.40) for paediatric patients. Misclassification as multiple sclerosis occurred in 55.0% Chang Gung Research Database and 63.5% National Health Insurance Research Database cohort. Misclassified patients were more likely to be younger, female, experience delayed antibody testing, have frequent hospitalizations, and suffer more relapses. Both hospital-based and nationwide cohorts revealed increasing neuromyelitis optica spectrum disorder incidence and prevalence in Taiwan. This early-phase elevation in relapse activity highlights the critical therapeutic window where intervention may most effectively prevent long-term disability. Greater clinical awareness and close follow-up may improve neuromyelitis optica spectrum disorder diagnosis and management.

Schlagwörter

Stichwörter der Autor:innen

ARRcomorbidityincidencemisclassificationneuromyelitis optica

Autor:innen und Institutionen

  • Department of Neurology, New Taipei Municipal TuCheng Hospital (Built and Operated by Chang Gung Medical Foundation), New Taipei City 236017, Taiwan.
  • Department of Neurology, Chang Gung Memorial Hospital Linkou Medical Center and College of Medicine, Chang-Gung University, Linkou, Taoyuan 333423, Taiwan.
  • Taipei Medical University, Graduate Institute of Humanities in Medicine and Research Center for Brain and Consciousness, Shuang Ho Hospital, Taipei 11031, Taiwan.
  • Department of Neurology, National Taiwan University Hospital, Taipei 106319, Taiwan.
  • Institute of Molecular Medicine, National Tsing Hua University, Hsinchu 30013, Taiwan.
  • Department of Public Health and School of Public Health, College of Public Health, Taipei Medical University, Taipei 11031, Taiwan.

ORCID-Profile: Jung Lung Hsu, Kuo-Hsuan Chang

Förderung

  • Chugai Pharma Taiwan Co, Ltd
  • Chang Gung Memorial Hospital Research Fund

Zitieren

APA

Hsu, J. L., Su, J. J., Cheng, M. Y., Liao, M. F., Kuo, H. C., Chu, C. C., Chen, C. M., Chang, K. H., Chang, C. W., Wu, Y. R., Huang, C. C., Bai, C. H., & Ro, L. S. (2025). Epidemiology and diagnostic challenges in neuromyelitis optica spectrum disorder in Taiwan: a hospital-based surveillance accompanied by a nationwide study. Brain Communications, 7(4). https://doi.org/10.1093/braincomms/fcaf293

Vancouver

Hsu JL, Su JJ, Cheng MY, Liao MF, Kuo HC, Chu CC, et al. Epidemiology and diagnostic challenges in neuromyelitis optica spectrum disorder in Taiwan: a hospital-based surveillance accompanied by a nationwide study. Brain Communications. 2025;7(4). doi:10.1093/braincomms/fcaf293

BibTeX
@article{Hsu2025,
  author = {Hsu, Jung Lung and Su, Jen Jen and Cheng, Mei-Yun and Liao, Ming-Feng and Kuo, Hung-Chou and Chu, Chun-Che and Chen, Chiung-Mei and Chang, Kuo-Hsuan and Chang, Chun-Wei and Wu, Yih-Ru and Huang, Chin-Chang and Bai, Chyi-Huey and Ro, Long-Sun},
  title = {Epidemiology and diagnostic challenges in neuromyelitis optica spectrum disorder in Taiwan: a hospital-based surveillance accompanied by a nationwide study},
  journal = {Brain Communications},
  year = {2025},
  volume = {7},
  number = {4},
  doi = {10.1093/braincomms/fcaf293}
}
Kostenlos starten →